TNFRSF17 and Miyoshi myopathy: Recently, B-cell maturation antigen (BCMA)-targeted CAR-T-cell therapies, such as idecabtagene vicleucel and ciltacabtagene autoleucel, have emerged as promising options, demonstrating high response rates in relapsed or refractory MM.